Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

A retrospective analysis of oropharyngeal patients with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 or 0522 found that HPV-positive patients had a higher overall survival (OS) rate than HPV-negative patients (at two years post-treatment, 54.6 percent vs. 27.6 percent, respectively), according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

20 Feb 2014

Severe skin reactions during radiation therapy could be prevented by applying silicone dressing

Severe skin reactions during radiation therapy could be prevented by applying a thin transparent silicone dressing to the skin from the first day of treatment, clinical research from New Zealand shows.

13 Feb 2014

Study reveals alarming increase in oropharyngeal cancers among young adults

A new study reveals an alarming increase in oropharyngeal cancers among young adults. While the exact cause for this phenomenon is unknown, the human papillomavirus (HPV) may be to blame.

30 Jan 2014

Simple protein test useful in predicting survival chances for patients with head-and-neck cancer

Scientists from The University of Manchester - part of the Manchester Cancer Research Centre - used a simple protein test that could prove more useful in predicting survival chances for patients with head-and-neck cancer compared to existing methods.

24 Jan 2014

Number of cancer stem cells in tumor might inaccurately estimate tumor's recurrence or progression

New research from The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that it may be the quality of cancer stem cells rather than their quantity that leads to better survival in certain patients with oral cancer.

23 Jan 2014

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.

21 Jan 2014

Lifestyle changes and screening tools prove to reduce cancer risk, says doctor

President Nixon funded research to wage a war on cancer, a long battle that we're still fighting today. While the last 40 years haven't brought us a cure, we have made some meaningful progress in developing tools and knowledge to take a bite out of our cancer risk.

10 Jan 2014

Nano-luteolin has immense potential for future studies of chemoprevention, say researchers

Researchers at the Winship Cancer Institute of Emory University have discovered a more effective drug delivery system using nanotechnology that could one day significantly affect cancer prevention.

8 Jan 2014

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today it has entered into a distribution agreement for Lymphoseek (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd., a leading in-country distributor of nuclear medicine and diagnostic imaging products.

7 Jan 2014

Johns Hopkins Kimmel Cancer Center scientists to receive $90M in new funding for cancer research

cientists at the Johns Hopkins Kimmel Cancer Center will receive $90 million in new funding as part of a $540 million gift from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig, to six U.S. institutions. The new award is among the largest for a single private gift to cancer research.

6 Jan 2014

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.

17 Dec 2013

Navidea receives Fast Track designation for Lymphoseek injection

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

11 Dec 2013

Study helps explain why survival gap persists for African-Americans with head and neck cancer

A team of scientists at Johns Hopkins and in Texas has identified a handful of genetic mutations in black Americans, in addition to some chemical alterations affecting gene activity, which may help explain why the death rate among African-Americans from the most common form of head and neck cancer continues to hover some 18 percent higher above the death rate of whites with the same cancer.

9 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

5 Dec 2013

Extract from bitter melon may have therapeutic qualities to treat head and neck cancer

Extract taken from an Asian vegetable may have therapeutic qualities to treat head and neck cancer, a Saint Louis University researcher has found.

19 Nov 2013

Cancer detection programme using PENTAX Medical equipment achieves remarkable results

PENTAX Medical equipment has been used to set up a pioneering head and neck cancer detection programme at a hospital Trust in Coventry, which has achieved remarkable results; reduced the length of time the patient stays in hospital and reduced costs.

From PENTAX Medical Company 8 Nov 2013

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, today announced the start of clinical testing with its EGFR-targeting ADC, IMGN289.

6 Nov 2013

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for HPV-associated head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.